Specifically, DAPA can inhibit hyperglycemia-induced upregulation of intercellular adhesion molecule-1 (ICAM-1), while EMPA inhibits certain chemokines such as monocyte chemoattractant protein-1 (MCP-1). The gene discussed is CCL2; the disease is Hyperglycemia.